tradingkey.logo

Baxter International Inc

BAX
18.960USD
-0.110-0.58%
收盘 12/19, 16:00美东报价延迟15分钟
9.74B总市值
亏损市盈率 TTM

Baxter International Inc

18.960
-0.110-0.58%

关于 Baxter International Inc 公司

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.

Baxter International Inc简介

公司代码BAX
公司名称Baxter International Inc
上市日期Jun 20, 2097
CEOHider (Andrew P)
员工数量38000
证券类型Ordinary Share
年结日Jun 20
公司地址One Baxter Parkway
城市DEERFIELD
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编60015
电话12249482000
网址https://www.baxter.com/
公司代码BAX
上市日期Jun 20, 2097
CEOHider (Andrew P)

Baxter International Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Andrew P. Hider
Mr. Andrew P. Hider
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
368.05K
--
Dr. Jeanne K. Mason, Ph.D.
Dr. Jeanne K. Mason, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
141.67K
+7.47%
Mr. David S. Rosenbloom
Mr. David S. Rosenbloom
Executive Vice President, General Counsel
Executive Vice President, General Counsel
101.60K
-14.01%
Dr. Stephen N. (Steve) Oesterle, M.D.
Dr. Stephen N. (Steve) Oesterle, M.D.
Independent Director
Independent Director
35.70K
+25.18%
Ms. Catherine R. (Cathy) Smith
Ms. Catherine R. (Cathy) Smith
Independent Director
Independent Director
30.23K
+31.17%
Ms. Patricia B. (Patty) Morrison
Ms. Patricia B. (Patty) Morrison
Independent Director
Independent Director
22.94K
+45.58%
Mr. Stephen H. (Steve) Rusckowski
Mr. Stephen H. (Steve) Rusckowski
Independent Director
Independent Director
16.45K
+77.49%
Mr. Jeffrey A. (Jay) Craig
Mr. Jeffrey A. (Jay) Craig
Independent Director
Independent Director
10.65K
+206.88%
Ms. Nancy M. Schlichting
Ms. Nancy M. Schlichting
Lead Independent Director
Lead Independent Director
7.97K
+912.71%
Ms. Amy A. Mcbride-Wendell
Ms. Amy A. Mcbride-Wendell
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Andrew P. Hider
Mr. Andrew P. Hider
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
368.05K
--
Dr. Jeanne K. Mason, Ph.D.
Dr. Jeanne K. Mason, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
141.67K
+7.47%
Mr. David S. Rosenbloom
Mr. David S. Rosenbloom
Executive Vice President, General Counsel
Executive Vice President, General Counsel
101.60K
-14.01%
Dr. Stephen N. (Steve) Oesterle, M.D.
Dr. Stephen N. (Steve) Oesterle, M.D.
Independent Director
Independent Director
35.70K
+25.18%
Ms. Catherine R. (Cathy) Smith
Ms. Catherine R. (Cathy) Smith
Independent Director
Independent Director
30.23K
+31.17%
Ms. Patricia B. (Patty) Morrison
Ms. Patricia B. (Patty) Morrison
Independent Director
Independent Director
22.94K
+45.58%

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Infusion Therapies and Technologies
1.02B
36.44%
Care and Connectivity Solutions
474.00M
16.87%
Injectables and Anesthesia
332.00M
11.81%
Advanced Surgery
296.00M
10.53%
Front Line Care
293.00M
10.43%
其他
391.00M
13.91%
地区USD
名称
营收
占比
United States
1.54B
54.66%
International
1.27B
45.34%
业务
地区
业务USD
名称
营收
占比
Infusion Therapies and Technologies
1.02B
36.44%
Care and Connectivity Solutions
474.00M
16.87%
Injectables and Anesthesia
332.00M
11.81%
Advanced Surgery
296.00M
10.53%
Front Line Care
293.00M
10.43%
其他
391.00M
13.91%

股东统计

更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
12.11%
Dodge & Cox
11.17%
Pzena Investment Management, LLC
11.16%
BlackRock Institutional Trust Company, N.A.
6.09%
BlackRock Financial Management, Inc.
4.80%
其他
54.66%
持股股东
持股股东
占比
The Vanguard Group, Inc.
12.11%
Dodge & Cox
11.17%
Pzena Investment Management, LLC
11.16%
BlackRock Institutional Trust Company, N.A.
6.09%
BlackRock Financial Management, Inc.
4.80%
其他
54.66%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
47.20%
Investment Advisor
44.83%
Hedge Fund
2.90%
Research Firm
2.48%
Pension Fund
1.50%
Insurance Company
1.45%
Bank and Trust
1.22%
Sovereign Wealth Fund
1.14%
Individual Investor
0.46%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
1743
527.76M
108.76%
+72.60K
2025Q3
1826
527.84M
110.04%
+1.85M
2025Q2
1880
509.50M
105.73%
+4.72M
2025Q1
1916
504.93M
105.92%
-38.38M
2024Q4
1965
494.73M
105.04%
+14.02M
2024Q3
1980
482.92M
103.29%
+12.67M
2024Q2
2019
470.33M
102.19%
-1.85M
2024Q1
2069
469.00M
102.47%
-52.95M
2023Q4
2111
469.21M
101.33%
+9.34M
2023Q3
2090
463.57M
98.58%
+5.62M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
61.95M
12.06%
+1.13M
+1.85%
Jun 30, 2025
Dodge & Cox
52.12M
10.15%
+662.70K
+1.29%
Jun 30, 2025
Pzena Investment Management, LLC
55.46M
10.8%
+16.12M
+40.98%
Aug 31, 2025
BlackRock Institutional Trust Company, N.A.
29.85M
5.81%
-423.57K
-1.40%
Jun 30, 2025
BlackRock Financial Management, Inc.
18.73M
3.65%
+742.99K
+4.13%
Jun 30, 2025
State Street Investment Management (US)
21.94M
4.27%
+170.66K
+0.78%
Jun 30, 2025
T. Rowe Price Associates, Inc.
21.21M
4.13%
+1.64M
+8.40%
Jun 30, 2025
Geode Capital Management, L.L.C.
12.88M
2.51%
+326.65K
+2.60%
Jun 30, 2025
BlackRock Investment Management, LLC
7.81M
1.52%
+818.08K
+11.70%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Large Cap Value Active ETF
2.23%
First Trust Indxx Medical Devices ETF
1.69%
Invesco Raymond James SB-1 Equity ETF
1.5%
State Street SPDR S&P Health Care Equipment ETF
1.37%
Invesco S&P 500 Equal Weight Health Care ETF
1.26%
Franklin US Dividend Booster Index ETF
1.26%
iShares U.S. Medical Devices ETF
1.13%
Invesco Zacks Multi-Asset Income ETF
0.8%
Humankind US Stock ETF
0.76%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
0.57%
查看更多
iShares Large Cap Value Active ETF
占比2.23%
First Trust Indxx Medical Devices ETF
占比1.69%
Invesco Raymond James SB-1 Equity ETF
占比1.5%
State Street SPDR S&P Health Care Equipment ETF
占比1.37%
Invesco S&P 500 Equal Weight Health Care ETF
占比1.26%
Franklin US Dividend Booster Index ETF
占比1.26%
iShares U.S. Medical Devices ETF
占比1.13%
Invesco Zacks Multi-Asset Income ETF
占比0.8%
Humankind US Stock ETF
占比0.76%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
占比0.57%

分红派息

近5年累计派现 2.75B 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Nov 11, 2025
BAX.NB Final Cash Dividend of gross USD 0.01 paid on Jan 02, 2026 going ex on Nov 28, 2025 with reinvestment option
Nov 28, 2025
Jan 02, 2026
Nov 28, 2025
Jul 14, 2025
BAX.NB Interim Cash Dividend of gross USD 0.17 paid on Oct 01, 2025 going ex on Aug 29, 2025 with reinvestment option
Aug 29, 2025
Oct 01, 2025
Aug 29, 2025
May 06, 2025
BAX.NB Interim Cash Dividend of gross USD 0.17 paid on Jul 01, 2025 going ex on May 30, 2025 with reinvestment option
May 30, 2025
Jul 01, 2025
May 30, 2025
Feb 11, 2025
BAX.NB Interim Cash Dividend of gross USD 0.17 paid on Apr 01, 2025 going ex on Feb 28, 2025 with reinvestment option
Feb 28, 2025
Apr 01, 2025
Feb 28, 2025
Nov 11, 2024
BAX.NB Final Cash Dividend of gross USD 0.17 paid on Jan 02, 2025 going ex on Nov 29, 2024 with reinvestment option
Nov 29, 2024
Jan 02, 2025
Nov 29, 2024
Jul 16, 2024
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Oct 01, 2024 going ex on Aug 30, 2024 with reinvestment option
Aug 30, 2024
Oct 01, 2024
Aug 30, 2024
May 07, 2024
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Jul 01, 2024 going ex on May 31, 2024 with reinvestment option
May 31, 2024
Jul 01, 2024
May 31, 2024
Feb 12, 2024
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Apr 01, 2024 going ex on Feb 29, 2024 with reinvestment option
Mar 01, 2024
Apr 01, 2024
Feb 29, 2024
Nov 14, 2023
BAX.NB Final Cash Dividend of gross USD 0.29 paid on Jan 02, 2024 going ex on Nov 30, 2023 with reinvestment option
Dec 01, 2023
Jan 02, 2024
Nov 30, 2023
Jul 18, 2023
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Oct 02, 2023 going ex on Aug 31, 2023 with reinvestment option
Sep 01, 2023
Oct 02, 2023
Aug 31, 2023
查看更多

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Baxter International Inc的前五大股东是谁?

Baxter International Inc 的前五大股东如下:
The Vanguard Group, Inc.持有股份:61.95M,占总股份比例:12.06%。
Dodge & Cox持有股份:52.12M,占总股份比例:10.15%。
Pzena Investment Management, LLC持有股份:55.46M,占总股份比例:10.80%。
BlackRock Institutional Trust Company, N.A.持有股份:29.85M,占总股份比例:5.81%。
BlackRock Financial Management, Inc.持有股份:18.73M,占总股份比例:3.65%。

Baxter International Inc的前三大股东类型是什么?

Baxter International Inc 的前三大股东类型分别是:
The Vanguard Group, Inc.
Dodge & Cox
Pzena Investment Management, LLC

有多少机构持有Baxter International Inc(BAX)的股份?

截至2025Q4,共有1743家机构持有Baxter International Inc的股份,合计持有的股份价值约为527.76M,占公司总股份的108.76%。与2025Q3相比,机构持股有所增加,增幅为-1.28%。

哪个业务部门对Baxter International Inc的收入贡献最大?

在FY2025Q2,Infusion Therapies and Technologies业务部门对Baxter International Inc的收入贡献最大,创收1.02B,占总收入的36.44%。
KeyAI